ArticleACS omega2026
Deciphering O‑GlcNAc-Dependent Signaling Via Integrated Proteomics and Phosphoproteomics.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-translational modifications (PTMs) on proteins play crucial roles in various biological processes. Two highly dynamic modifications, phosphorylation and O-linked N-acetylglucosamine modification (O-GlcNAcylation), are essential for cellular physiology and pathology. Emerging evidence suggests intimate crosstalk between phosphorylation and O-GlcNAcylation on multiple proteins. However, the precise nature of their crosstalk remains largely unknown. In this study, we explored the crosstalk between phosphorylation and O-GlcNAcylation using the pancreatic ductal cell line PANC-1 as a model. Proteome and phosphoproteome changes were measured for cells treated with OSMI-1, a specific inhibitor of O-GlcNAc transferase, and Thiamet G, a specific inhibitor of O-GlcNAcase. Among the 8938 phosphorylation sites quantified, 2289 phosphosites on 1225 proteins and 2201 phosphosites on 1199 proteins were significantly altered by OSMI-1 and TMG treatment, respectively, demonstrating extensive crosstalk between O-GlcNAcylation and phosphorylation. Further analysis revealed widespread phosphorylation changes of the kinome and phosphatome, even after a short-term perturbation with inhibitors to O-GlcNAc cycling enzymes. Moreover, phosphoproteomic profiling, kinase inhibition experiments, and in vitro kinase assays identified that phosphorylation of OGA itself at S364 is specifically mediated by casein kinase 2 α (CK2α). These results uncover glycosylation-dependent cellular signaling through the potentially multilayer crosstalk between phosphorylation and O-GlcNAcylation.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.